BridgeBio Pharma Sees 193% Q3 Revenue Surge and Anticipation for New Treatments
BBIO BridgeBio Pharma Inc
$78.67 +0.95%
View chart & analysis → - 1BridgeBio Pharma reported total Q3 revenue of $353.2 million.
- 2BridgeBio Pharma announced positive Phase 3 clinical results for BBP-418.
- 3BridgeBio Pharma entered into a $1 billion preferred equity financing partnership.
So what's the key point?
BridgeBio Pharma saw a 193% increase in revenue during the third quarter and received positive test results for a new drug. Expectations for the company have grown following a $1 billion investment partnership.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.